Predictive Value of Individualized Tumor Response Testing by ATP-Based Chemotherapy Response Assay in Ovarian Cancer

REFERENCES

• Jemal A., Siegel R., Ward E., Murray T., Xu J., et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56(2)106–130
   PubMed Web of Science ®Google Scholar
• McGuire W. P., Hoskins W. J., Brady M. F., Kucera P. R., Partridge E. E., et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 1996; 23(5 Suppl 12)40–47
   PubMed Web of Science ®Google Scholar
• Ozols R. F., Bundy B. N., Greer B. E., Fowler J. M., Clarke-Pearson D., , Phase I II, et al. trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21(17)3194–3200
   PubMed Web of Science ®Google Scholar
• Cree I. A., Kurbacher C. M. Individualizing chemotherapy for solid tumors–is there any alternative?. Anticancer Drugs 1997; 8(6)541–548
   PubMed Web of Science ®Google Scholar
• Weisenthal L. M., Marsden J. A., Dill P. L., Macaluso C. K. A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res 1983; 43(2)749–757
   PubMed Web of Science ®Google Scholar
• Kern D. H., Drogemuller C. R., Kennedy M. C., Hildebrand-Zanki S. U., Tanigawa N., Sondak V. K. Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors. Cancer Res 1985; 45: 5436–5441, (11 Pt 1)
   PubMed Web of Science ®Google Scholar
• Andreotti P. E., Cree I. A., Kurbacher C. M., Hartmann D. M., Linder D., et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55(22)5276–5282
   PubMed Web of Science ®Google Scholar
• Sevin B. U., Peng Z. L., Perras J. P., Ganjei P., Penalver M., Averette H. E. Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecol Oncol 1988; 31(1)191–204
   PubMed Web of Science ®Google Scholar
• Cree I. A., Kurbacher C. M., Untch M., Sutherland L. A., Hunter E. M., et al. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anticancer Drugs 1996; 7(6)630–635
   PubMed Web of Science ®Google Scholar
• O'Meara A. T., Sevin B. U. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer. Gynecol Oncol 2001; 83(2)334–342
   PubMed Web of Science ®Google Scholar
• Kawamura H., Ikeda K., Takiyama I., Terashima M. The usefulness of the ATP assay with serum-free culture for chemosensitivity testing of gastrointestinal cancer. Eur J Cancer 1997; 33(6)960–966
   PubMed Web of Science ®Google Scholar
• Konecny G., Crohns C., Pegram M., Felber M., Lude S., et al. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 2000; 77(2)258–263
   PubMed Web of Science ®Google Scholar
• Sharma S., Neale M. H., Di Nicolantonio F., Knight L. A., Whitehouse P. A., et al. Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer 2003; 3: 19
   PubMedGoogle Scholar
• Kang S. M., Park M. S., Chang J., Kim S. K., Kim H., Shin D. H. A Feasibility Study of Adenosine Triphosphate-based Chemotherapy Response Assay (ATP-CRA) as a Chemosensitivity Test for Lung Cancer. Cancer Res Treat 2005; 37(4)223–227
   PubMedGoogle Scholar
• Moon Y. W., Choi S. H., Kim Y. T., Sohn J. H., Chang J., et al. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer. Cancer 2007; 109(9)1829–1835
   PubMed Web of Science ®Google Scholar
• Iinuma H., Okinaga K., Adachi M., Suda K., Sekine T., et al. Detection of tumor cells in blood using CD45 magnetic cell separation followed by nested mutant allele-specific amplification of p53 and K-ras genes in patients with colorectal cancer. Int J Cancer 2000; 89(4)337–344
   PubMed Web of Science ®Google Scholar
• Weisenthal L. M., Dill P. L., Finklestein J. Z., Duarte T. E., Baker J. A., Moran E. M. Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms. Cancer Treat Rep 1986; 70(11)1283–1295
   PubMedGoogle Scholar
• Bird M. C., Bosanquet A. G., Gilby E. D. In vitro determination of tumour chemosensitivity in haematological malignancies. Hematol Oncol 1985; 3(1)1–10
   PubMed Web of Science ®Google Scholar
• Von, Hoff D. D., Casper J., Bradley E., Sandbach J., Jones D., Makuch R. Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med 1981; 70(5)1027–1041
   PubMed Web of Science ®Google Scholar
• Therasse P., Arbuck S. G., Eisenhauer E. A., Wanders J., Kaplan R. S., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3)205–216
   PubMed Web of Science ®Google Scholar
• Rustin G. J., Quinn M., Thigpen T., du, Bois A., Pujade-Lauraine E., et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004; 96(6)487–488
   PubMed Web of Science ®Google Scholar
• Jeong J., Lee S., Yoon S., Jung W., Lee H., Lee I. Clinical availability of chemotherapy response assay using adenosine triphosphate in breast cancer patients. Proceedings of the American Society of Clinical Oncology 2006, Abstract 15592
   Google Scholar
• Kim B. S., Ahn Y. M., Kim J., Yoon E. J., Choi S. H. Clinical utility of adenosine triphosphate-based chemosensitivity response assay (ATP-CRA) in non-small cell lung cancer: Preliminary study. Proceedings of the American Society of Clinical Oncology 2004, Abstract 7259
   Web of Science ®Google Scholar
• Kim H. A., Yom C. K., Moon B. I., Choe K. J., Sung S. H., et al. The use of an in vitro adenosine triphosphate-based chemotherapy response assay to predict chemotherapeutic response in breast cancer. Breast 2007, July 27
   Web of Science ®Google Scholar
• Ng T. Y., Ngan H. Y., Cheng D. K., Wong L. C. Clinical applicability of the ATP cell viability assay as a predictor of chemoresponse in platinum-resistant epithelial ovarian cancer using nonsurgical tumor cell samples. Gynecol Oncol 2000; 76(3)405–408
   PubMed Web of Science ®Google Scholar
• Ozols R. F. Chemotherapy of ovarian cancer. Cancer Treat Res 1998; 95: 219–234
   PubMedGoogle Scholar
• Schrag D., Garewal H. S., Burstein H. J., Samson D. J., Von Hoff D. D., Somerfield M. R. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 2004; 22(17)3631–3638
   PubMed Web of Science ®Google Scholar
• Cortazar P., Johnson B. E. Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol 1999; 17(5)1625–1631
   PubMed Web of Science ®Google Scholar
• Orr J. W., Jr., Orr P., Kern D. H. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance. Cancer J Sci Am 1999; 5(3)174–178
   PubMed Web of Science ®Google Scholar
• Smith N. F., Marsh S., Scott-Horton T. J., Hamada A., Mielke S., et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007; 81(1)76–82
   PubMed Web of Science ®Google Scholar